[Abstract Only] In a Phase 2 randomized trial, Semaglutide at high doses improved Nonalcoholic Steatohepatitis (NASH), but with no significant beneficial effects in liver fibrosis

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Semaglutide Shows Promise in NASH Phase 2 Study – Medscape (free registration required)

Commentary on Twitter

https://twitter.com/NEJM/status/1327238536001593346